Universal Beteiligungs und Servicegesellschaft mbH Raises Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has increased its stake in PTC Therapeutics by 33.6%, acquiring an additional 36,365 shares for a total of 144,710 shares valued at approximately $7.37 million as of the latest reporting period.
• PTC Therapeutics reported $10.04 earnings per share for the quarter, significantly beating analysts' expectations of $0.85 EPS and generating revenue of $1.18 billion, which is down 9.6% compared to the previous year.
• Wall Street analysts have mixed views on PTC Therapeutics, with a range of ratings leading to an average target price of $65.00, and notable upgrades from firms like Bank of America and Wells Fargo.

Universal Beteiligungs und Servicegesellschaft mbH grew its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 33.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 144,710 shares of the biopharmaceutical company's stock after acquiring an additional 36,365 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.18% of PTC Therapeutics worth $7,374,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in PTCT. Edgestream Partners L.P. acquired a new stake in PTC Therapeutics during the first quarter worth $418,000. CWM LLC grew its stake in shares of PTC Therapeutics by 390.9% in the first quarter. CWM LLC now owns 17,756 shares of the biopharmaceutical company's stock valued at $905,000 after buying an additional 14,139 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of PTC Therapeutics by 8.5% in the first quarter. New York State Common Retirement Fund now owns 25,421 shares of the biopharmaceutical company's stock valued at $1,295,000 after buying an additional 2,000 shares in the last quarter. Xponance Inc. grew its stake in shares of PTC Therapeutics by 5.2% in the first quarter. Xponance Inc. now owns 6,372 shares of the biopharmaceutical company's stock valued at $325,000 after buying an additional 314 shares in the last quarter. Finally, Cerity Partners LLC acquired a new stake in shares of PTC Therapeutics in the first quarter valued at $641,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Robert W. Baird dropped their price objective on PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. JPMorgan Chase & Co. lowered their target price on PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. UBS Group boosted their target price on PTC Therapeutics from $71.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday. Royal Bank Of Canada upped their price objective on PTC Therapeutics from $57.00 to $58.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 7th. Finally, Wall Street Zen cut PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 16th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, PTC Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $69.38.

PTC Therapeutics Price Performance

NASDAQ PTCT traded up $5.79 on Tuesday, hitting $50.13. 1,779,311 shares of the company's stock were exchanged, compared to its average volume of 1,031,265. The firm's 50-day moving average price is $48.81 and its two-hundred day moving average price is $48.56. PTC Therapeutics, Inc. has a fifty-two week low of $29.01 and a fifty-two week high of $58.38. The firm has a market cap of $3.97 billion, a price-to-earnings ratio of 7.69 and a beta of 0.50.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $9.19. The company had revenue of $1.18 billion for the quarter, compared to analysts' expectations of $437.16 million. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The firm's quarterly revenue was down 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.20) EPS. On average, research analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Mark Elliott Boulding sold 883 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $46.02, for a total value of $40,635.66. Following the sale, the vice president owned 103,901 shares in the company, valued at $4,781,524.02. This represents a 0.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Pierre Gravier sold 2,516 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $49.46, for a total value of $124,441.36. Following the completion of the sale, the chief financial officer owned 71,920 shares in the company, valued at approximately $3,557,163.20. This represents a 3.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,328 shares of company stock worth $254,158. Insiders own 5.50% of the company's stock.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.